Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 19/20 | 0.55 |
| ▸ | ARG2 | P78540 | 17/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18079486 | 0.92 | ARG2 (0.46) | ARG1ARG2 | |
| SCHEMBL20683472 | 0.90 | ARG1 (0.64) | ARG1ARG2 | |
| SCHEMBL10006164 | 0.88 | ARG1 (0.52) | ARG1ARG2 | |
| SCHEMBL10006212 | 0.87 | ARG1 (0.53) | ARG1ARG2 | |
| SCHEMBL10006086 | 0.87 | ARG2 (0.48) | ARG1ARG2 | |
| SCHEMBL10006244 | 0.84 | ARG2 (0.46) | ARG1ARG2 | |
| SCHEMBL10006227 | 0.83 | ARG1 (0.53) | ARG1ARG2 | |
| SCHEMBL29657572 | 0.83 | ARG1 (0.53) | ARG1ARG2 | |
| SCHEMBL895198 | 0.82 | ARG2 (0.59) | ARG1ARG2 | |
| SCHEMBL18079466 | 0.81 | ARG1 (0.54) | ARG1ARG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8894970-B2 | Arginase inhibitors and methods of use thereof | CORRIDOR PHARMACEUTICALS, INC. (US) | 2014-11-25 | — | — | US | claimed |
| US-20120171116-A1 | Arginase Inhibitors and Methods of Use Thereof | CORRIDOR PHARMACEUTICALS, INC. | 2012-07-05 | — | — | US | claimed |
| WO-2023283332-A1 | USES OF ARGINASE INHIBITORS FOR MANAGING KIDNEY DISEASE AND CARDIOVASCULAR CONDITIONS | EMORY UNIVERSITY (US) | 2023-01-12 | — | — | WO | disclosed |
| CN-110123820-B | Arginase inhibitors and methods of use thereof | 阿斯利康公司 | 2022-05-31 | — | — | CN | disclosed |
| US-9447122-B2 | Arginase inhibitors and methods of use thereof | ASTRAZENECA AB (SE) | 2016-09-20 | — | — | US | disclosed |
| US-9447122-B2 | Arginase inhibitors and methods of use thereof | ASTRAZENECA AB (SE) | 2016-09-20 | — | — | US | disclosed |
| US-20160039847-A1 | Arginase Inhibitors and Methods of Use Thereof | ASTRAZENECA AB (SE) | 2016-02-11 | — | — | US | disclosed |
| US-8894970-B2 | Arginase inhibitors and methods of use thereof | CORRIDOR PHARMACEUTICALS, INC. (US) | 2014-11-25 | — | — | US | disclosed |
| EP-2658580-A1 | ARGINASE INHIBITORS AND METHODS OF USE THEREOF | Corridor Pharmaceuticals, Inc. (US) | 2013-11-06 | — | — | EP | disclosed |
| US-20120171116-A1 | Arginase Inhibitors and Methods of Use Thereof | CORRIDOR PHARMACEUTICALS, INC. | 2012-07-05 | — | — | US | disclosed |
| WO-2012091757-A1 | ARGINASE INHIBITORS AND METHODS OF USE THEREOF | CORRIDOR PHARMACEUTICALS, INC. (US) | 2012-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120171116-A1 | Arginase Inhibitors and Methods of Use Thereof | ARG1, ARG2, PRMT1 | ARG1 1/4885ARG2 2/4885 |
| US-20160039847-A1 | Arginase Inhibitors and Methods of Use Thereof | ARG1, ARG2, PRMT1 | ARG1 1/4885ARG2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.